Genmab A/S (NASDAQ:GMAB) and Alaunos Therapeutics (NASDAQ:TCRT) Financial Survey
Genmab A/S (NASDAQ:GMAB) and Alaunos Therapeutics (NASDAQ:TCRT) Financial Survey
Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) and Genmab A/S (NASDAQ:GMAB – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.
納斯達克(代碼：TCRT-GET Rating)和基因泰克A/S(納斯達克代碼：GMAB-GET Rating)都是醫療公司，但哪一項投資更具優勢？我們將根據這兩家公司的盈利能力、股息、機構所有權、估值、收益、風險和分析師建議的強弱對它們進行比較。
Valuation & Earnings
估值與收益
This table compares Alaunos Therapeutics and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.
下表比較了ALaunos Treateutics和Genmab A/S的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alaunos Therapeutics | $400,000.00 | 350.81 | -$78.75 million | ($0.19) | -3.42 |
| Genmab A/S | $1.35 billion | 20.72 | $478.57 million | $1.22 | 34.74 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| ALaunos治療公司 | $400,000.00 | 350.81 | -7,875萬元 | ($0.19) | -3.42 |
| Genmab A/S | 13.5億美元 | 20.72 | 4.7857億美元 | $1.22 | 34.74 |
Genmab A/S has higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Genmab A/S的收入和收益高於ALaunos治療公司。ALaunos治療公司的市盈率低於Genmab A/S，這表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Alaunos Therapeutics | N/A | -88.31% | -49.35% |
| Genmab A/S | 46.32% | 22.78% | 20.33% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| ALaunos治療公司 | 不適用 | -88.31% | -49.35% |
| Genmab A/S | 46.32% | 22.78% | 20.33% |
Analyst Ratings
分析師評級
This is a breakdown of recent ratings and recommmendations for Alaunos Therapeutics and Genmab A/S, as provided by MarketBeat.com.
這是MarketBeat.com提供的ALaunos治療公司和Genmab A/S公司最近的評級和推薦細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alaunos Therapeutics | 0 | 2 | 2 | 0 | 2.50 |
| Genmab A/S | 2 | 11 | 3 | 0 | 2.06 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| ALaunos治療公司 | 0 | 2 | 2 | 0 | 2.50 |
| Genmab A/S | 2 | 11 | 3 | 0 | 2.06 |
Alaunos Therapeutics currently has a consensus target price of $2.50, indicating a potential upside of 285.15%. Genmab A/S has a consensus target price of $38.55, indicating a potential downside of 9.05%. Given Alaunos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Alaunos Therapeutics is more favorable than Genmab A/S.
ALaunos治療公司目前的共識目標價為2.5美元，表明潛在上漲285.15%。Genmab A/S的共識目標價為38.55美元，表明潛在下行9.05%。鑑於ALaunos治療公司更高的共識評級和更高的可能上行空間，分析師們顯然認為ALaunos治療公司比Genmab A/S更有利。
Risk & Volatility
風險與波動性
Alaunos Therapeutics has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.
ALaunos治療公司的貝塔係數為0.07，這表明其股價的波動性比標準普爾500指數低93%。相比之下，Genmab A/S的貝塔係數為0.99，這表明其股價的波動性比標準普爾500指數低1%。
Institutional & Insider Ownership
機構與內部人持股
34.4% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Genmab A/S shares are owned by institutional investors. 4.9% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ALaunos治療公司34.4%的股份由機構投資者持有。相比之下，Genmab A/S公司6.7%的股份由機構投資者持有。ALaunos治療公司4.9%的股份由公司內部人士持有。相比之下，Genmab A/S公司1.5%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一隻股票有望實現長期增長。
Summary
摘要
Genmab A/S beats Alaunos Therapeutics on 9 of the 14 factors compared between the two stocks.
Genmab A/S在兩隻股票之間比較的14個因素中有9個擊敗了ALaunos Treateutics。
About Alaunos Therapeutics
ALaunos治療公司簡介
(Get Rating)
(獲取評級)
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
ALaunos治療公司是一家專注於臨牀階段腫瘤學的細胞治療公司，開發採用TCR工程的T細胞療法。該公司開發了TCR文庫，該文庫對10個對突變的KRAS、TP53和EGFR產生反應的TCR進行了I/II期臨牀試驗，這些TCR文庫用於治療非小細胞肺癌、結直腸癌、子宮內膜癌、胰腺癌、卵巢癌和膽管癌；人類腫瘤抗原T細胞受體平臺HunTR；以及用於治療實體腫瘤的MBIL-15。ALaunos治療公司與PGEN治療公司簽訂了許可協議；與德克薩斯大學MD安德森癌症中心簽訂了研發協議；與美國國家癌症研究所簽訂了專利許可協議和研發協議。該公司前身為ZIOPHARM腫瘤學公司，並於2022年1月更名為ALaunos治療公司。ALaunos治療公司總部設在得克薩斯州休斯敦。
About Genmab A/S
關於Genmab A/S
(Get Rating)
(獲取評級)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/S主要在丹麥開發用於治療癌症和其他疾病的抗體療法。該公司銷售用於治療多發性骨髓瘤(MM)患者的人類單抗DARZALEX；用於治療甲狀腺眼病的teprotomumab；用於治療慢性淋巴細胞白血病(CLL)和多發性硬化症的人類單抗Ofatumurnab；以及用於晚期或轉移性胃癌、食道癌和非小細胞肺癌的Amivantamab。其產品包括用於治療MM、非MM血癌和AL澱粉樣變性的daratumab；GEN1047；用於治療宮頸癌、卵巢癌和實體瘤的tisotomab vedotin；用於治療實體瘤的DuoBody-PD-L1x4-1BB和DuoBody-CD40x4-1BB；用於復發/難治性瀰漫性大B細胞淋巴瘤和慢性淋巴細胞白血病的Epcoritamab；以及用於治療血液系統惡性腫瘤的HexaBody-CD38和DuoHexaBody-CD37。該公司還開發處於第二階段的產品，包括用於血管閉塞危機的Tecistamab；用於治療霍奇金淋巴瘤和實體瘤的CamidanLumab Tesiine；用於治療MM的JNJ-64007957和JNJ-64407564；用於治療乳糜瀉的PRV-015；用於治療血友病A的MIM8；以及用於治療多系統萎縮性疾病的Lu AF82422。此外，它還有大約20個活躍的臨牀前項目。該公司與Seagen Inc.有商業許可和合作協議，共同開發tisotomab vedotin。它還與CureVac AG簽訂了研究和開發不同的基於信使核糖核酸的抗體產品的合作協議；AbbVie公司開發epcoritamab；與BioNTech公司、Janssen公司、Novo Nordisk A/S公司、Blink Biomedical SAS公司和Bolt BioTreateutics公司合作。Genmab A/S公司成立於1999年，總部設在丹麥哥本哈根。
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ALaunos治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ALaunos治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。